Cargando…

Application of Pharmacokinetic-Pharmacodynamic Modeling to Inform Translation of In Vitro NaV1.7 Inhibition to In Vivo Pharmacological Response in Non-human Primate

PURPOSE: This work describes a staged approach to the application of pharmacokinetic-pharmacodynamic (PK-PD) modeling in the voltage-gated sodium ion channel (NaV1.7) inhibitor drug discovery effort to address strategic questions regarding in vitro to in vivo translation of target modulation. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Ballard, Jeanine E., Pall, Parul, Vardigan, Joshua, Zhao, Fuqiang, Holahan, Marie A., Kraus, Richard, Li, Yuxing, Henze, Darrell, Houghton, Andrea, Burgey, Christopher S., Gibson, Christopher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7473964/
https://www.ncbi.nlm.nih.gov/pubmed/32888082
http://dx.doi.org/10.1007/s11095-020-02914-9
_version_ 1783579258146258944
author Ballard, Jeanine E.
Pall, Parul
Vardigan, Joshua
Zhao, Fuqiang
Holahan, Marie A.
Kraus, Richard
Li, Yuxing
Henze, Darrell
Houghton, Andrea
Burgey, Christopher S.
Gibson, Christopher
author_facet Ballard, Jeanine E.
Pall, Parul
Vardigan, Joshua
Zhao, Fuqiang
Holahan, Marie A.
Kraus, Richard
Li, Yuxing
Henze, Darrell
Houghton, Andrea
Burgey, Christopher S.
Gibson, Christopher
author_sort Ballard, Jeanine E.
collection PubMed
description PURPOSE: This work describes a staged approach to the application of pharmacokinetic-pharmacodynamic (PK-PD) modeling in the voltage-gated sodium ion channel (NaV1.7) inhibitor drug discovery effort to address strategic questions regarding in vitro to in vivo translation of target modulation. METHODS: PK-PD analysis was applied to data from a functional magnetic resonance imaging (fMRI) technique to non-invasively measure treatment mediated inhibition of olfaction signaling in non-human primates (NHPs). Initial exposure-response was evaluated using single time point data pooled across 27 compounds to inform on in vitro to in vivo correlation (IVIVC). More robust effect compartment PK-PD modeling was conducted for a subset of 10 compounds with additional PD and PK data to characterize hysteresis. RESULTS: The pooled compound exposure-response facilitated an early exploration of IVIVC with a limited dataset for each individual compound, and it suggested a 2.4-fold in vitro to in vivo scaling factor for the NaV1.7 target. Accounting for hysteresis with an effect compartment PK-PD model as compounds advanced towards preclinical development provided a more robust determination of in vivo potency values, which resulted in a statistically significant positive IVIVC with a slope of 1.057 ± 0.210, R-squared of 0.7831, and p value of 0.006. Subsequent simulations with the PK-PD model informed the design of anti-nociception efficacy studies in NHPs. CONCLUSIONS: A staged approach to PK-PD modeling and simulation enabled integration of in vitro NaV1.7 potency, plasma protein binding, and pharmacokinetics to describe the exposure-response profile and inform future study design as the NaV1.7 inhibitor effort progressed through drug discovery. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s11095-020-02914-9) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-7473964
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-74739642020-09-16 Application of Pharmacokinetic-Pharmacodynamic Modeling to Inform Translation of In Vitro NaV1.7 Inhibition to In Vivo Pharmacological Response in Non-human Primate Ballard, Jeanine E. Pall, Parul Vardigan, Joshua Zhao, Fuqiang Holahan, Marie A. Kraus, Richard Li, Yuxing Henze, Darrell Houghton, Andrea Burgey, Christopher S. Gibson, Christopher Pharm Res Research Paper PURPOSE: This work describes a staged approach to the application of pharmacokinetic-pharmacodynamic (PK-PD) modeling in the voltage-gated sodium ion channel (NaV1.7) inhibitor drug discovery effort to address strategic questions regarding in vitro to in vivo translation of target modulation. METHODS: PK-PD analysis was applied to data from a functional magnetic resonance imaging (fMRI) technique to non-invasively measure treatment mediated inhibition of olfaction signaling in non-human primates (NHPs). Initial exposure-response was evaluated using single time point data pooled across 27 compounds to inform on in vitro to in vivo correlation (IVIVC). More robust effect compartment PK-PD modeling was conducted for a subset of 10 compounds with additional PD and PK data to characterize hysteresis. RESULTS: The pooled compound exposure-response facilitated an early exploration of IVIVC with a limited dataset for each individual compound, and it suggested a 2.4-fold in vitro to in vivo scaling factor for the NaV1.7 target. Accounting for hysteresis with an effect compartment PK-PD model as compounds advanced towards preclinical development provided a more robust determination of in vivo potency values, which resulted in a statistically significant positive IVIVC with a slope of 1.057 ± 0.210, R-squared of 0.7831, and p value of 0.006. Subsequent simulations with the PK-PD model informed the design of anti-nociception efficacy studies in NHPs. CONCLUSIONS: A staged approach to PK-PD modeling and simulation enabled integration of in vitro NaV1.7 potency, plasma protein binding, and pharmacokinetics to describe the exposure-response profile and inform future study design as the NaV1.7 inhibitor effort progressed through drug discovery. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s11095-020-02914-9) contains supplementary material, which is available to authorized users. Springer US 2020-09-04 2020 /pmc/articles/PMC7473964/ /pubmed/32888082 http://dx.doi.org/10.1007/s11095-020-02914-9 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Paper
Ballard, Jeanine E.
Pall, Parul
Vardigan, Joshua
Zhao, Fuqiang
Holahan, Marie A.
Kraus, Richard
Li, Yuxing
Henze, Darrell
Houghton, Andrea
Burgey, Christopher S.
Gibson, Christopher
Application of Pharmacokinetic-Pharmacodynamic Modeling to Inform Translation of In Vitro NaV1.7 Inhibition to In Vivo Pharmacological Response in Non-human Primate
title Application of Pharmacokinetic-Pharmacodynamic Modeling to Inform Translation of In Vitro NaV1.7 Inhibition to In Vivo Pharmacological Response in Non-human Primate
title_full Application of Pharmacokinetic-Pharmacodynamic Modeling to Inform Translation of In Vitro NaV1.7 Inhibition to In Vivo Pharmacological Response in Non-human Primate
title_fullStr Application of Pharmacokinetic-Pharmacodynamic Modeling to Inform Translation of In Vitro NaV1.7 Inhibition to In Vivo Pharmacological Response in Non-human Primate
title_full_unstemmed Application of Pharmacokinetic-Pharmacodynamic Modeling to Inform Translation of In Vitro NaV1.7 Inhibition to In Vivo Pharmacological Response in Non-human Primate
title_short Application of Pharmacokinetic-Pharmacodynamic Modeling to Inform Translation of In Vitro NaV1.7 Inhibition to In Vivo Pharmacological Response in Non-human Primate
title_sort application of pharmacokinetic-pharmacodynamic modeling to inform translation of in vitro nav1.7 inhibition to in vivo pharmacological response in non-human primate
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7473964/
https://www.ncbi.nlm.nih.gov/pubmed/32888082
http://dx.doi.org/10.1007/s11095-020-02914-9
work_keys_str_mv AT ballardjeaninee applicationofpharmacokineticpharmacodynamicmodelingtoinformtranslationofinvitronav17inhibitiontoinvivopharmacologicalresponseinnonhumanprimate
AT pallparul applicationofpharmacokineticpharmacodynamicmodelingtoinformtranslationofinvitronav17inhibitiontoinvivopharmacologicalresponseinnonhumanprimate
AT vardiganjoshua applicationofpharmacokineticpharmacodynamicmodelingtoinformtranslationofinvitronav17inhibitiontoinvivopharmacologicalresponseinnonhumanprimate
AT zhaofuqiang applicationofpharmacokineticpharmacodynamicmodelingtoinformtranslationofinvitronav17inhibitiontoinvivopharmacologicalresponseinnonhumanprimate
AT holahanmariea applicationofpharmacokineticpharmacodynamicmodelingtoinformtranslationofinvitronav17inhibitiontoinvivopharmacologicalresponseinnonhumanprimate
AT krausrichard applicationofpharmacokineticpharmacodynamicmodelingtoinformtranslationofinvitronav17inhibitiontoinvivopharmacologicalresponseinnonhumanprimate
AT liyuxing applicationofpharmacokineticpharmacodynamicmodelingtoinformtranslationofinvitronav17inhibitiontoinvivopharmacologicalresponseinnonhumanprimate
AT henzedarrell applicationofpharmacokineticpharmacodynamicmodelingtoinformtranslationofinvitronav17inhibitiontoinvivopharmacologicalresponseinnonhumanprimate
AT houghtonandrea applicationofpharmacokineticpharmacodynamicmodelingtoinformtranslationofinvitronav17inhibitiontoinvivopharmacologicalresponseinnonhumanprimate
AT burgeychristophers applicationofpharmacokineticpharmacodynamicmodelingtoinformtranslationofinvitronav17inhibitiontoinvivopharmacologicalresponseinnonhumanprimate
AT gibsonchristopher applicationofpharmacokineticpharmacodynamicmodelingtoinformtranslationofinvitronav17inhibitiontoinvivopharmacologicalresponseinnonhumanprimate